» Articles » PMID: 33840079

Experiences and Perspectives of Patients with Non-HIV-Associated Lipodystrophies and Their Caregivers: A Qualitative Study

Overview
Journal Patient
Specialty Health Services
Date 2021 Apr 11
PMID 33840079
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lipodystrophy comprises a group of conditions characterized by loss of functional adipose tissue, resulting in severe metabolic complications and a complex range of symptoms.

Objective: This study sought to gain a holistic understanding of the impact of congenital or non-human immunodeficiency virus acquired lipodystrophies on the quality of life of patients and their caregivers and to capture the impact of lipodystrophy on quality of life using a standard instrument.

Methods: Ten patients with lipodystrophies and five caregivers from the USA and UK were recruited through convenience sampling and interviewed using a semi-structured questionnaire containing open-ended questions about disease symptoms and attributes and numerical rating scales to prompt discussion of symptom prevalence and impact. After the interview, participants filled out the 36-Item Short Form (SF-36) survey instrument. Conventional conceptual content analysis methods were used to analyze the anonymized transcripts.

Results: Four concepts were developed: diagnostic journey and symptom management, burden of disease, healthcare resource utilization, and support and advocacy. Participants described lengthy diagnostic journeys and frequent interactions with healthcare systems. Many participants became experts on lipodystrophy through the diagnostic journey and described difficulties accessing effective treatment, even after diagnosis. Both patients and caregivers emphasized the ongoing burden of living with lipodystrophy and the accompanying sense of isolation. Participants turned to disease-specific support groups to cope, engaging in knowledge sharing with other patients and caregivers and developing friendships based on shared experiences. Ten participants completed the SF-36, with a mean (standard deviation) SF-36 score of 0.6 (0.2).

Conclusions: Currently, there are no qualitative studies that describe the experiences of patients with lipodystrophy and their caregivers. While additional research is needed, educational work like this study is a promising first step that could lead to early diagnosis and access to treatment and support.

Citing Articles

Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey.

Patni N, Chard C, Araujo-Vilar D, Phillips H, Magee D, Akinci B Orphanet J Rare Dis. 2024; 19(1):263.

PMID: 38992753 PMC: 11241872. DOI: 10.1186/s13023-024-03245-3.


Impact of lipodystrophy on health-related quality of life: the QuaLip study.

Demir T, Yildirim Simsir I, Tuncel O, Ozbaran B, Yildirim I, Pirildar S Orphanet J Rare Dis. 2024; 19(1):10.

PMID: 38183080 PMC: 10768358. DOI: 10.1186/s13023-023-03004-w.


Qualitative interviews in patients with lipodystrophy to assess the patient experience: evaluation of hunger and other symptoms.

Martin S, Sanchez R, Olayinka-Amao O, Harris C, Fehnel S J Patient Rep Outcomes. 2022; 6(1):84.

PMID: 35904713 PMC: 9338178. DOI: 10.1186/s41687-022-00486-3.

References
1.
Garg A . Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011; 96(11):3313-25. PMC: 7673254. DOI: 10.1210/jc.2011-1159. View

2.
Garg A . Acquired and inherited lipodystrophies. N Engl J Med. 2004; 350(12):1220-34. DOI: 10.1056/NEJMra025261. View

3.
Arioglu Oral E, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P . Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002; 346(8):570-8. DOI: 10.1056/NEJMoa012437. View

4.
Chiquette E, Oral E, Garg A, Araujo-Vilar D, Dhankhar P . Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017; 10:375-383. PMC: 5604558. DOI: 10.2147/DMSO.S130810. View

5.
Budych K, Helms T, Schultz C . How do patients with rare diseases experience the medical encounter? Exploring role behavior and its impact on patient-physician interaction. Health Policy. 2012; 105(2-3):154-64. DOI: 10.1016/j.healthpol.2012.02.018. View